Masthead

A ROSALIND® Case Study: Differentially expressed miRNAs in single hormone receptor-positive breast cancer

Masthead
  • 11:00 am - 12:00 pm
Speakers: Jerid Robinson, PhD Field Application Scientist NanoString Technologies

Estrogen (ER) and progesterone (PgR) receptors and HER2 are crucial in the assessment of breast cancer specimens due to their prognostic and predictive significance. Single hormone receptor-positive breast cancers are less common and their clinical course is less favorable than ER(+)/PgR(+) tumors. In this study, the main differences in miRNA expression amongst single hormone receptor-positive tumors were identified according to their HER2 status. miRNA expression profiling was done with the NanoString® nCounter® Human v3 miRNA Expression Assay and analyzed using ROSALIND powered by OnRamp Bio. miRNA expression in ER(−)/PgR(+) tumors resemble triple- and double-negative tumors, which may indicate that their biology is similar to basal-like carcinomas. ER(+)/PgR(−) tumors show higher expression of miRNAs typical for double-positive luminal carcinomas. The main differences in miRNA expression amongst single hormone receptor-positive tumors were found to be related to their HER2 status rather than to their hormonal receptor status. The effect on mRNA expression was estimated for four available miRNA-mRNA pairs (TGFB2–miR-141-3p, NEDD4L–miR-30a-5p, FGFR4–miR-424-5p, & SOCS2–miR-424-5p) was assessed, but no significant results were obtained.

For Research Use Only.  Not for Use in Diagnostic Procedures.